Eisai Inc Drug Patent Portfolio

Eisai Inc owns 9 orange book drugs protected by 58 US patents with Aricept Odt having the least patent protection, holding only 2 patents. And Belviq Xr with maximum patent protection, holding 17 patents. Given below is the list of Eisai Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11090386 Method for suppressing bitterness of quinoline derivative 23 Aug, 2036
Active
US12083112 Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer 03 Mar, 2036
Active
US10259791 High-purity quinoline derivative and method for manufacturing same 26 Feb, 2036
Active
US10407393 High-purity quinoline derivative and method for manufacturing same 26 Feb, 2036
Active
US11186547 High-purity quinoline derivative and method for manufacturing same 26 Feb, 2036
Active
US11090386 Method for suppressing bitterness of quinoline derivative 23 Feb, 2036
Active
US10188652 Compositions and methods for treating insomnia 21 Oct, 2035
Active
US10702529 Compositions and methods for treating insomnia 21 Oct, 2035
Active
US11026944 Compositions and methods for treating insomnia 21 Oct, 2035
Active
US10259791 High-purity quinoline derivative and method for manufacturing same 26 Aug, 2035
Active
US10407393 High-purity quinoline derivative and method for manufacturing same 26 Aug, 2035
Active
US11186547 High-purity quinoline derivative and method for manufacturing same 26 Aug, 2035
Active
US8999970 Administration of an anti-obesity compound to individuals with renal impairment 07 Feb, 2033
Active
US9169213 Method of weight management 06 Dec, 2032
Active
US8268848 Cyclopropane compound 20 Sep, 2031
Active
US9770455 Administration of an anti-obesity compound to individuals with renal impairment 31 Aug, 2031
Active
US10226471 Modified-release dosage forms of 5-HT2C agonists useful for weight management 31 Aug, 2031
Active
US10463676 Modified-release dosage forms of 5-HT2C agonists useful for weight management 31 Aug, 2031
Active
US8168624 Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride 18 Apr, 2029
Active
US9006256 Antitumor agent for thyroid cancer 27 Jan, 2028
Active
US9006256 Antitumor agent for thyroid cancer 27 Jul, 2027
Active
USRE46965 Intermediates for the preparation of analogs of Halichondrin B 08 Jul, 2027
Active
US7612208 Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same 19 Mar, 2027
Active
USRE46965 Intermediates for the preparation of analogs of Halichondrin B 08 Jan, 2027
Active
US8481565 Method for stabilizing anti-dementia drug 04 Oct, 2026
Active
US7612208 Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same 19 Sep, 2026
Active
US7253286 Nitrogen-containing aromatic derivatives 24 Apr, 2026
Active
US8697686 Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride 20 Dec, 2025
Active
US8980881 Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride 20 Dec, 2025
Active
US7253286 Nitrogen-containing aromatic derivatives 24 Oct, 2025
Active
US8946207 Processes for preparing 3-benzazepines 16 Jun, 2024 Expired
US6214865 Macrocyclic analogs and methods of their use and preparation 20 Jan, 2024 Expired
US7169401 Topical skin care composition containing refined peanut oil 18 Jul, 2023 Expired
US6740669 Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic 14 May, 2023 Expired
US6953787 5HT2C receptor modulators 10 Apr, 2023 Expired
US7514422 5HT2c receptor modulators 10 Apr, 2023 Expired
US7977329 5HT2C receptor modulators 10 Apr, 2023 Expired
US8207158 5HT2c receptor modulators 10 Apr, 2023 Expired
US8273734 5HT2C receptor modulators 10 Apr, 2023 Expired
US8367657 Processes for preparing 3-benzazepines 10 Apr, 2023 Expired
US8546379 5HT2C receptor modulators 10 Apr, 2023 Expired
US8575149 5HT2C receptor modulators 10 Apr, 2023 Expired
US6740669 Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic 14 Nov, 2022 Expired
US6204257 Water soluble prodrugs of hindered alcohols 01 Jul, 2022 Expired
US7727548 Rapidly disintegrable tablet containing polyvinyl alcohol 23 Jun, 2022 Expired
US8097648 Methods and compositions for use in treating cancer 22 Jan, 2021 Expired
US6214865 Macrocyclic analogs and methods of their use and preparation 16 Jun, 2019 Expired
US6469182 Intermediates in the preparation of macrocyclic analogs 16 Jun, 2019 Expired
US7470720 Methods and compositions for use in treating cancer 16 Jun, 2019 Expired
US7750028 Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide 19 Apr, 2019 Expired
US8076362 Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof 08 Dec, 2018 Expired
US6245911 Donepezil polycrystals and process for producing the same 01 Dec, 2018 Expired
US7750028 Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide 19 Oct, 2018 Expired
US6872838 Water soluble prodrugs of hindered alcohols 07 Aug, 2018 Expired
US8076362 Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof 08 Jun, 2018 Expired
US7727552 Oral pharmaceutical preparations decreased in bitterness by masking 26 Mar, 2018 Expired
US5985864 Polymorphs of donepezil hydrochloride and process for production 30 Dec, 2016 Expired
US6140321 Polymorphs of donepezil hydrochloride and process for production 30 Dec, 2016 Expired


Given below is the list of recent legal activities going on the following drug patents of Eisai Inc.

Activity Date Patent Number
Patent litigations
Maintenance Fee Reminder Mailed 13 May, 2024 US8273734 (Litigated)
Maintenance Fee Reminder Mailed 13 May, 2024 US8273734 (Litigated)
Interim Patent Term Extension Granted 21 Mar, 2024 US6953787 (Litigated)
Interim Patent Term Extension Granted 21 Mar, 2024 US6953787 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 11 Mar, 2024 US8268848
Expire Patent 19 Feb, 2024 US8097648
Maintenance Fee Reminder Mailed 12 Feb, 2024 US8207158 (Litigated)
Maintenance Fee Reminder Mailed 12 Feb, 2024 US8207158 (Litigated)
Post Issue Communication - Certificate of Correction 04 Jan, 2024 US8168624
Post Issue Communication - Certificate of Correction 04 Jan, 2024 US8168624
Payment of Maintenance Fee, 4th Year, Large Entity 28 Dec, 2023 US10702529
PTE Interim Patent Extension filed 21 Dec, 2023 US6953787 (Litigated)
Requirement for information sent under 37 CFR 1.750 21 Dec, 2023 US6953787 (Litigated)
Requirement for information sent under 37 CFR 1.750 21 Dec, 2023 US6953787 (Litigated)
PTE Interim Patent Extension filed 21 Dec, 2023 US6953787 (Litigated)


Eisai Inc's Drug Patent Litigations

Eisai Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 22, 2003, against patent number US6740669. The petitioner , challenged the validity of this patent, with ROBERT PORTMANN et al as the respondent. Click below to track the latest information on how companies are challenging Eisai Inc's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6740669 April, 2003 Decision
(17 Nov, 2003)
ROBERT PORTMANN et al


Eisai Inc Drug Patents' Oppositions Filed in EPO

Eisai Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 18, 2016, by Actavis Group Ptc Ehf. This opposition was filed on patent number EP07743994A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP19151846A May, 2023 Welding GmbH & Co. KG Granted and Under Opposition
EP19151846A May, 2023 Accord Healthcare Granted and Under Opposition
EP19151846A May, 2023 STADA Arzneimittel AG Granted and Under Opposition
EP19151846A May, 2023 Generics (U.K.) Limited Granted and Under Opposition
EP19151846A May, 2023 Aechter, Bernd Granted and Under Opposition
EP19151846A May, 2023 Maiwald GmbH Granted and Under Opposition
EP19151846A May, 2023 Hansen, Norbert Granted and Under Opposition
EP19151846A May, 2023 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP19151846A May, 2023 ELKINGTON AND FIFE LLP Granted and Under Opposition
EP07743994A Jul, 2016 Generics [UK] Ltd (trading as Mylan) Revoked
EP07743994A Jul, 2016 Actavis Group PTC ehf Revoked


Eisai Inc's Family Patents

Eisai Inc drugs have patent protection in a total of 42 countries. It's US patent count contributes only to 17.6% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Eisai Inc Drug List

Given below is the complete list of Eisai Inc's drugs and the patents protecting them.


1. Aricept

Aricept is protected by 4 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8481565 Method for stabilizing anti-dementia drug 04 Oct, 2026
(1 year, 11 months from now)
Active
US6245911 Donepezil polycrystals and process for producing the same 01 Dec, 2018
(5 years ago)
Expired
US5985864 Polymorphs of donepezil hydrochloride and process for production 30 Dec, 2016
(7 years ago)
Expired
US6140321 Polymorphs of donepezil hydrochloride and process for production 30 Dec, 2016
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aricept's drug page


2. Aricept Odt

Aricept Odt is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7727548 Rapidly disintegrable tablet containing polyvinyl alcohol 23 Jun, 2022
(2 years ago)
Expired
US7727552 Oral pharmaceutical preparations decreased in bitterness by masking 26 Mar, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aricept Odt's drug page


3. Banzel

Banzel is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6740669
(Pediatric)
Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic 14 May, 2023
(1 year, 4 months ago)
Expired
US6740669 Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic 14 Nov, 2022
(1 year, 10 months ago)
Expired
US7750028
(Pediatric)
Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide 19 Apr, 2019
(5 years ago)
Expired
US8076362
(Pediatric)
Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof 08 Dec, 2018
(5 years ago)
Expired
US7750028 Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide 19 Oct, 2018
(5 years ago)
Expired
US8076362 Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof 08 Jun, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Banzel's drug page


4. Belviq

Belviq is protected by 16 patents, out of which 10 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8999970 Administration of an anti-obesity compound to individuals with renal impairment 07 Feb, 2033
(8 years from now)
Active
US9169213 Method of weight management 06 Dec, 2032
(8 years from now)
Active
US9770455 Administration of an anti-obesity compound to individuals with renal impairment 31 Aug, 2031
(6 years from now)
Active
US8168624 Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride 18 Apr, 2029
(4 years from now)
Active
US8697686 Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride 20 Dec, 2025
(1 year, 2 months from now)
Active
US8980881 Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride 20 Dec, 2025
(1 year, 2 months from now)
Active
US8946207 Processes for preparing 3-benzazepines 16 Jun, 2024
(3 months ago)
Expired
US7169401 Topical skin care composition containing refined peanut oil 18 Jul, 2023
(1 year, 2 months ago)
Expired
US6953787 5HT2C receptor modulators 10 Apr, 2023
(1 year, 6 months ago)
Expired
US7514422 5HT2c receptor modulators 10 Apr, 2023
(1 year, 6 months ago)
Expired
US7977329 5HT2C receptor modulators 10 Apr, 2023
(1 year, 6 months ago)
Expired
US8207158 5HT2c receptor modulators 10 Apr, 2023
(1 year, 6 months ago)
Expired
US8273734 5HT2C receptor modulators 10 Apr, 2023
(1 year, 6 months ago)
Expired
US8367657 Processes for preparing 3-benzazepines 10 Apr, 2023
(1 year, 6 months ago)
Expired
US8546379 5HT2C receptor modulators 10 Apr, 2023
(1 year, 6 months ago)
Expired
US8575149 5HT2C receptor modulators 10 Apr, 2023
(1 year, 6 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Belviq's drug page


5. Belviq Xr

Belviq Xr is protected by 17 patents, out of which 9 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8999970 Administration of an anti-obesity compound to individuals with renal impairment 07 Feb, 2033
(8 years from now)
Active
US9169213 Method of weight management 06 Dec, 2032
(8 years from now)
Active
US10226471 Modified-release dosage forms of 5-HT2C agonists useful for weight management 31 Aug, 2031
(6 years from now)
Active
US10463676 Modified-release dosage forms of 5-HT2C agonists useful for weight management 31 Aug, 2031
(6 years from now)
Active
US9770455 Administration of an anti-obesity compound to individuals with renal impairment 31 Aug, 2031
(6 years from now)
Active
US8168624 Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride 18 Apr, 2029
(4 years from now)
Active
US8697686 Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride 20 Dec, 2025
(1 year, 2 months from now)
Active
US8980881 Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride 20 Dec, 2025
(1 year, 2 months from now)
Active
US8946207 Processes for preparing 3-benzazepines 16 Jun, 2024
(3 months ago)
Expired
US6953787 5HT2C receptor modulators 10 Apr, 2023
(1 year, 6 months ago)
Expired
US7514422 5HT2c receptor modulators 10 Apr, 2023
(1 year, 6 months ago)
Expired
US7977329 5HT2C receptor modulators 10 Apr, 2023
(1 year, 6 months ago)
Expired
US8207158 5HT2c receptor modulators 10 Apr, 2023
(1 year, 6 months ago)
Expired
US8273734 5HT2C receptor modulators 10 Apr, 2023
(1 year, 6 months ago)
Expired
US8367657 Processes for preparing 3-benzazepines 10 Apr, 2023
(1 year, 6 months ago)
Expired
US8546379 5HT2C receptor modulators 10 Apr, 2023
(1 year, 6 months ago)
Expired
US8575149 5HT2C receptor modulators 10 Apr, 2023
(1 year, 6 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Belviq Xr's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Dayvigo

Dayvigo is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10188652 Compositions and methods for treating insomnia 21 Oct, 2035
(11 years from now)
Active
US10702529 Compositions and methods for treating insomnia 21 Oct, 2035
(11 years from now)
Active
US11026944 Compositions and methods for treating insomnia 21 Oct, 2035
(11 years from now)
Active
US8268848 Cyclopropane compound 20 Sep, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dayvigo's drug page


7. Halaven

Halaven is protected by 7 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
USRE46965
(Pediatric)
Intermediates for the preparation of analogs of Halichondrin B 08 Jul, 2027
(2 years from now)
Active
USRE46965 Intermediates for the preparation of analogs of Halichondrin B 08 Jan, 2027
(2 years from now)
Active
US6214865
(Pediatric)
Macrocyclic analogs and methods of their use and preparation 20 Jan, 2024
(8 months ago)
Expired
US8097648 Methods and compositions for use in treating cancer 22 Jan, 2021
(3 years ago)
Expired
US6214865 Macrocyclic analogs and methods of their use and preparation 16 Jun, 2019
(5 years ago)
Expired
US6469182 Intermediates in the preparation of macrocyclic analogs 16 Jun, 2019
(5 years ago)
Expired
US7470720 Methods and compositions for use in treating cancer 16 Jun, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Halaven's drug page


8. Lenvima

Lenvima is protected by 15 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11090386
(Pediatric)
Method for suppressing bitterness of quinoline derivative 23 Aug, 2036
(11 years from now)
Active
US12083112 Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer 03 Mar, 2036
(11 years from now)
Active
US10259791
(Pediatric)
High-purity quinoline derivative and method for manufacturing same 26 Feb, 2036
(11 years from now)
Active
US10407393
(Pediatric)
High-purity quinoline derivative and method for manufacturing same 26 Feb, 2036
(11 years from now)
Active
US11186547
(Pediatric)
High-purity quinoline derivative and method for manufacturing same 26 Feb, 2036
(11 years from now)
Active
US11090386 Method for suppressing bitterness of quinoline derivative 23 Feb, 2036
(11 years from now)
Active
US10259791 High-purity quinoline derivative and method for manufacturing same 26 Aug, 2035
(10 years from now)
Active
US10407393 High-purity quinoline derivative and method for manufacturing same 26 Aug, 2035
(10 years from now)
Active
US11186547 High-purity quinoline derivative and method for manufacturing same 26 Aug, 2035
(10 years from now)
Active
US9006256
(Pediatric)
Antitumor agent for thyroid cancer 27 Jan, 2028
(3 years from now)
Active
US9006256 Antitumor agent for thyroid cancer 27 Jul, 2027
(2 years from now)
Active
US7612208
(Pediatric)
Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same 19 Mar, 2027
(2 years from now)
Active
US7612208 Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same 19 Sep, 2026
(1 year, 11 months from now)
Active
US7253286
(Pediatric)
Nitrogen-containing aromatic derivatives 24 Apr, 2026
(1 year, 6 months from now)
Active
US7253286 Nitrogen-containing aromatic derivatives 24 Oct, 2025
(1 year, 11 days from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lenvima's drug page


9. Lusedra

Lusedra is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6204257 Water soluble prodrugs of hindered alcohols 01 Jul, 2022
(2 years ago)
Expired
US6872838 Water soluble prodrugs of hindered alcohols 07 Aug, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lusedra's drug page


Eisai Inc News

Eisai in Japan considers using blood test to determine eligibility for Alzheimer's drug - Nikkei Asia

25 Jul, 2024

FDA Approves Second Medication for Slowing Alzheimer's Disease Progression

03 Jul, 2024

Eisai and Merck file lawsuit against Dr. Reddy's to prevent generic versions of Lenvima

06 Jun, 2024

Antiepileptic Drugs Market Expected to Surpass $26.30 Billion by 2031 Amid Regulatory and Safety Challenges...

09 Apr, 2024

See More